Receptors providing targeted costimulation for adoptive cell therapy
US11945876B2 · kind B2 · utility
1Cited by
39References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 15, 2022 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Jun 15, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.